MENU
RGEN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Repligen (RGEN) Ownership - Who owns Repligen?
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
41 Seyon Street
Phone
+1 781 250-0111
Employees
1783
Web
https://www.repligen.com
Details
Group
Domestic Stock Funds
Category
Medical Specialties
Capitalization
10.26B
P/E Ratio
247.52
Total Cash
751.32M
Projected Growth
N/A
Total Debt
711.8M
Revenue
638.76M
Risk (Beta)
1.21
Dividend Yield
N/A
Total Cash/Share
13.47
Total Debt/Equity
N/A
Revenue/Share
11.33 USD as % of share price
Fundamentals
RGEN
Capitalization
10.3B
P/E Ratio
247.52
Risk (Beta)
1.21
Dividend Yield
N/A
Total Cash
751M
Total Cash/Share
13.47
Total Debt
712M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
11.33%
Revenue
639M
ROE
N/A
Book Value
1.97B
P/B Ratio
5.18
Cash Flow
N/A
Earnings
0.75
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
558K
Current Ratio
7.02
Current Revenue Per Employee
87348.85
Dividends Per Share - Security
N/A
EBITDA
134M
Float
N/A
Float - Current
N/A
Gross Income Margin
43.41
Revenue To Assets
1.55
Shares Held By Institutions
20.1B
Shares Outstanding - Current
55.8M
Total Liabilities
853M
Total Volume MTD
N/A
Value
-1
Gain YTD
-9.045
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a developer of biologic drugs
Industry MedicalSpecialties
Profile
Fundamentals
Details
Industry
Biotechnology
Address
41 Seyon Street
Phone
+1 781 250-0111
Employees
1783
Web
https://www.repligen.com